Zobrazeno 1 - 10 of 152 pro vyhledávání: '"E R, van Wering"'
1
EVI1 overexpression in distinct subtypes of pediatric acute myeloid leukemia
Autor: Susan T.J.C.M. Arentsen-Peters, S S N de Graaf, H B Beverloo, Sanne Lugthart, Martin Zimmermann, Jan Stary, Christian M. Zwaan, M M van den Heuvel-Eibrink, Brian V. Balgobind, E. S. J. M. de Bont, E. R. Van Wering, Gertjan J.L. Kaspers, U. Creutzig, Ruud Delwel, Dirk Reinhardt, Rob Pieters, Jan Trka, Iris H.I.M. Hollink
Publikováno v: Balgobind, B V, Lugthart, S, Hollink, I H, Arentsen-Peters, S T J C, van Wering, E R, de Graaf, S S N, Reinhardt, D, Creutzig, U, Kaspers, G J L, De Bont, E S J M, Stary, J, Trka, J, Zimmermann, M, Beverloo, HB, Pieters, R, Delwel, R, Zwaan, C M & van den Heuvel-Eibrink, M 2010, ' EVI1 overexpression in distinct subtypes of pediatric acute myeloid leukemia ', Leukemia, vol. 24, no. 5, pp. 942-949 . https://doi.org/10.1038/leu.2010.47
Leukemia, 24(5), 942-949. Nature Publishing Group
Leukemia, 24, 5, pp. 942-9
Leukemia, 24, 942-9
Overexpression of the ecotropic virus integration-1 (EVI1) gene (EVI1+), localized at chromosome 3q26, is associated with adverse outcome in adult acute myeloid leukemia (AML). In pediatric AML, 3q26 abnormalities are rare, and the role of EVI1 is un
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e59d65e51c1e72198779c4988960cc79
https://doi.org/10.1038/leu.2010.47
Zobrazit plný text záznamu
2
Genome-wide expression analysis of paired diagnosis–relapse samples in ALL indicates involvement of pathways related to DNA replication, cell cycle and DNA repair, independent of immune phenotype
Autor: V H J van der Velden, Denise T. D. de Ridder, J. J. M. Van Dongen, Tomasz Szczepański, E C E van der Linden, Tom Schonewille, F J T Staal, E. R. Van Wering
Publikováno v: Leukemia, 24(3), 491-499. Nature Publishing Group
Almost a quarter of pediatric patients with acute lymphoblastic leukemia (ALL) suffer from relapses. The biological mechanisms underlying therapy response and development of relapses have remained unclear. In an attempt to better understand this phen
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ca21c57160a3918a7b6071eacbf0222
https://doi.org/10.1038/leu.2009.286
Zobrazit plný text záznamu
3
Preemptive alloimmune intervention in high-risk pediatric acute lymphoblastic leukemia patients guided by minimal residual disease level before stem cell transplantation
Autor: Juul T. Wijnen, Tom Revesz, R M Egeler, M.J.D. van Tol, Marco W. Schilham, A.C. Lankester, V H J van der Velden, B. Versluys, Annemarie J. M. Wijkhuijs, E. R. Van Wering, R.A. de Weger, Jaak M. Vossen, J. J. M. Van Dongen, Marc Bierings, Hein Putter
Publikováno v: Leukemia, 24(8), 1462-1469. Nature Publishing Group
Leukemia, 24(8), 1462-9
Leukemia, 24(8), 1462-1469
Relapse of pediatric acute lymphoblastic leukemia (ALL) remains the main cause of treatment failure after allogeneic stem cell transplantation (alloSCT). A high level of minimal residual disease (MRD) before alloSCT has been shown to predict these re
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee3164ef1221fe7c16cafd07eb67bdef
https://doi.org/10.1038/leu.2010.133
Zobrazit plný text záznamu
4
Ontwikkelingen in de diagnostiek en behandeling van leukemie bij kinderen met downsyndroom
Autor: V H J van der Velden, Marjolein Blink, T. Buitenkamp, E. R. Van Wering, J.P. van Wouwe, Christian M. Zwaan
Publikováno v: Tijdschrift voor Kindergeneeskunde, 77(2), 52-58. Bohn Stafleu van Loghum
Children with Down syndrome (DS) have an increased risk for developing both acute myeloid as well as acute lymphoblastic leukemia. These leukemias differ in clinical characteristics and biology compared to leukemias in non-DS children. Moreover, chil
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ed834788b3ef8610e77b2f325d59d8a
https://doi.org/10.1007/bf03086357
Zobrazit plný text záznamu
6
Prognostic significance of molecular-cytogenetic abnormalities in pediatric T-ALL is not explained by immunophenotypic differences
Autor: A.W. Langerak, M. van Grotel, E.M.M. (Esther) van Lieshout, Rob Pieters, M. Passier, M. M. van Noesel, Jessica G.C.A.M. Buijs-Gladdines, Jules P.P. Meijerink, E. R. Van Wering, N. B. Burger, Willem Kamps, H B Beverloo, Anjo J.P. Veerman
Publikováno v: Leukemia, 22(1), 124-131. Nature Publishing Group
Leukemia, 22(1), 124-31. Nature Publishing Group
van Grotel, M, Meijerink, J P, van Wering, E R, Langerak, A W, Beverloo, HB, Buijs-Gladdines, J G, Burger, N B, Passier, M, van Lieshout, E M, Kamps, W A, Veerman, A J P, van Noesel, M M & Pieters, R 2008, ' Prognostic significance of molecular-cytogenetic abnormalities in pediatric T-ALL is not explained by immunophenotypic differences ', Leukemia, vol. 22, no. 1, pp. 124-131 . https://doi.org/10.1038/sj.leu.2404957
Leukemia, 22, 124-131. Nature Publishing Group
Pediatric T-cell acute lymphoblastic leukemia (T-ALL) is characterized by chromosomal rearrangements possibly enforcing arrest at specific development stages. We studied the relationship between molecular- cytogenetic abnormalities and T-cell develop
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf7c3d7d583d3e32649d57e5ac7b7637
https://doi.org/10.1038/sj.leu.2404957
Zobrazit plný text záznamu
7
Incidence of additional genetic changes in the TEL and AML1 genes in DCOG and COALL-treated t(12;21)-positive pediatric ALL, and their relation with drug sensivity and clinical outcome
Autor: G. E. Janka-Schaub, R. X de Menezes, W A G Stams, E. R. Van Wering, M L den Boer, Rob Pieters, A. H. Loonen, E van Drunen, N L Ramakers-van-Woerden, R L Stigter, H B Beverloo
Publikováno v: Leukemia, 20, 410-416. Nature Publishing Group
Clinical heterogeneity within t(12;21) or TEL/AML1-positive ALL (25% of childhood common/preB ALL) indicates that additional genetic changes might contribute to outcome. We studied the relation between additional genetic changes in TEL(ETV6) and AML1
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6fb66404e434a64819b037cc43aea5b1
https://pure.eur.nl/en/publications/15f4b858-62f1-4066-b318-97974154c3f7
Zobrazit plný text záznamu
8
Differential expression of p73 isoforms in relation to drug resistance in childhood T-lineage acute lymphoblastic leukaemia
Autor: M. Meier, Jules P.P. Meijerink, Rob Pieters, M L den Boer, Mathilde J.C. Broekhuis, E. R. Van Wering, G. E. Janka-Schaub, Monique Passier
Publikováno v: Leukemia, 20, 1377-1384. Nature Publishing Group
The T-lineage phenotype of childhood acute lymphoblastic leukaemia (ALL) is associated with an increased relapse-risk and in vitro resistance to drugs as compared to a precursor B phenotype. Antiapoptotic isoforms of p73 that lack part of the transac
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ee0606d8ee54e0d2f81d2e795d53209
https://doi.org/10.1038/sj.leu.2404288
Zobrazit plný text záznamu
9
The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia
Autor: E. R. Van Wering, Gertjan J.L. Kaspers, G.J. Peters, U Creutzig, Ronald W. Stam, Isabelle Hubeek, Christian M. Zwaan, Rob Pieters, Dirk J. Kuik, Jules P.P. Meijerink, Jacqueline Cloos, Richard Broekhuizen, Brenda Gibson
Publikováno v: British Journal of Cancer
British Journal of Cancer, 93(12), 1388-1394. Nature Publishing Group
Cytarabine (ara-C) is the most effective agent for the treatment of acute myeloid leukaemia (AML). Aberrant expression of enzymes involved in the transport/metabolism of ara-C could explain drug resistance. We determined mRNA expression of these fact
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e227daa3059a14d1c8d0e8d996ccacc0
http://europepmc.org/articles/PMC2361532
Zobrazit plný text záznamu
10
Treatment strategy and results in children treated on three Dutch Childhood Oncology Group acute myeloid leukemia trials
Autor: Jos P.M. Bökkerink, Gertjan J.L. Kaspers, G. Kardos, E. S. J. M. de Bont, A. van der Does-van den Berg, S S N de-Graaf, Albert Postma, R.S. Weening, E. R. Van Wering, Christian M. Zwaan, C Korbijn, Karel Hählen
Publikováno v: Leukemia, 19, 2063-71
Leukemia, 19, 12, pp. 2063-71
Leukemia, 19(12), 2063-2071. Nature Publishing Group
Kardos, G, Zwaan, C M, Kaspers, G J L, de Graaf, SS, de Bont, ES, Postma, A, Bokkerink, JP, Weening, R S, van den Berg, A, van Wering, E R, Korbijn, C & Hahlen, K 2005, ' Treatment strategy and results in children treated on three Dutch Childhood Oncology Group acute myeloid leukemia trials ', Leukemia, vol. 19, no. 12, pp. 2063-2071 . https://doi.org/10.1038/sj.leu.2403873
Contains fulltext : 49234.pdf (Publisher’s version ) (Closed access) This report describes the long-term follow-up data of three consecutive Dutch Childhood Oncology Group acute myeloid leukemia (AML) protocols. A total of 303 children were diagnos
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::caf0f27704a73480e0a99cc1915d9b76
https://hdl.handle.net/1871/26719
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje